Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300771 | 1.00 | MAPK14 (0.47) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL3997550 | 0.91 | MAPK14 (0.40) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL3997548 | 0.91 | MAPK14 (0.40) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL3992817 | 0.84 | MAPK14 (0.66) | MAPK14ALDH1A1SMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL29593607 | 0.84 | MAPK14 (0.66) | MAPK14ALDH1A1SMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL5780689 | 0.82 | MAPK14 (0.47) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL3993063 | 0.82 | MAPK14 (0.72) | MAPK14 | |
| SCHEMBL4530604 | 0.80 | MAPK14 (0.51) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL4528981 | 0.80 | MAPK14 (0.40) | MAPK14ALDH1A1SMN1; SMN2FABP4DYRK1A | |
| SCHEMBL3996767 | 0.75 | MAPK14 (0.59) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPK14 174/4885ALDH1A1 3145/4885SMN1; SMN2 4199/4885 |
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPK14 174/4885ALDH1A1 3145/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.